5th CNS Drug Delivery

As neuroscience R and D surges with investment to solve the field's most pressing challenge, access to the brain, the 5th CNS Drug Development Summit will provide an unmissable showcase of the latest innovations to revolutionize therapeutic administration routes to the brain and optimize dose specificity. Join neuroscientists, neurobiologists, neuro-oncologists, protein engineers, biochemists, and CNS device experts from the likes of Roche, AbbVie, Takeda, Lundbeck, Sanofi, Biogen, Alnylam Pharmaceuticals and Bristol Myers Squibb this December as they reunite to translate their novel brain delivery technologies into the clinic. 

URLs:
Tickets: https://go.evvnt.com/1879346-2?pid=185
Brochure: https://go.evvnt.com/1879346-3?pid=185

Prices:
Drug Developer Pricing - Conference + Workshop Day: USD 4096.00,
Drug Developer Pricing - Conference Only: USD 2599.00,
Solution Provider Pricing - Conference + Workshop Day: USD 6046.00,
Solution Provider Pricing - Conference Only: USD 3799.00

Speakers: Adem Koksal, Scientific Director, Biologics Drug Discovery, Biogen, Allan Jensen, Vice President, Lundbeck, Aloïse Mabondzo, Co-Founder, CERES Brain Therapeutics, Anu Bhattacharyya, Executive Director, PTC Therapeutics, Bellos Hadjivassiliou, Senior Principal Scientist, Bristol-Meyers Squibb, Bryn Martin, Vice President, Research, Precision Delivery and CSF Sciences, Alcyone Therapeutics, Cheng-Chia Wu, Assistant Professor, Columbia University Irving Medical Center, Darin Falk, Chief Scientific Officer, Lacerta Therapeutics, Didier Lefebvre, Research Fellow, Abbvie, Felix Schumacher, Program Leader Targeted Therapeutics, Roche, Fergus Quigley, Director, Device Development Leader (Early Stage), Takeda, Habib Baghirov, Scientific Lead, Roche, Haiyan Peng, Principal Scientist, Alnylam Pharmaceuticals, Iosif Pediaditakis, Associate Director of Neuroscience, Alchemab Therapeutics, Jeff Kurz, Associate Director, Alnylam Pharmaceuticals, Keri Kasun, Associate Medical Director, Biogen, Leah Sabin, Executive Director, Regeneron, Max Nowak, Senior Scientist, Viridian Therapeutics, Nathalie Agar, Associate Professor of Neurosurgery and of Radiology, Harvard Medical School, Niels Janssen, Group Head DMPK/PD, Roche, Panna Sharma, Chief Executive Officer, Lantern Pharma, Patrick Wen, Professor of Neurology, Harvard Medical School; Director, Center For Neuro-Oncology, Dana-Farber Cancer Instutute,  Dana-Farber Cancer Institute, Quan Jin, Senior Scientist - Gene Therapy Accelerator Unit, Biogen, Sabyasachi Dash, Senior Scientist, Alexion-AstraZeneca Rare Disease, Shyam Ramachandran, Senior Group Head, Neurologic Diseases, Sanofi, Smrithi Padmakumar, Drug Product Development Senior Scientist, Spark Therapeutics, Stephan Mittermeyer, Vice President, Therapeutic Strategies, CNS Gene Therapy, Asklepios BioPharmaceutical (AskBio), Suganya Selvarajah, Director of Biology, Attralus, William Elmquist, Distinguished Professor, Department of Pharmaceutics, University of Minnesota

Time: 8:00 am to 5:00 pm